X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs DR. REDDYS LAB - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD DR. REDDYS LAB WYETH LTD/
DR. REDDYS LAB
 
P/E (TTM) x 27.7 29.2 94.8% View Chart
P/BV x 5.3 2.9 186.6% View Chart
Dividend Yield % 1.3 0.9 135.1%  

Financials

 WYETH LTD   DR. REDDYS LAB
EQUITY SHARE DATA
    WYETH LTD
Mar-13
DR. REDDYS LAB
Mar-17
WYETH LTD/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,0443,397 30.7%   
Low Rs8182,560 32.0%   
Sales per share (Unadj.) Rs298.6856.5 34.9%  
Earnings per share (Unadj.) Rs57.278.0 73.4%  
Cash flow per share (Unadj.) Rs58.4139.9 41.8%  
Dividends per share (Unadj.) Rs17.0020.00 85.0%  
Dividend yield (eoy) %1.80.7 271.9%  
Book value per share (Unadj.) Rs249.5739.8 33.7%  
Shares outstanding (eoy) m22.72165.74 13.7%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.13.5 89.7%   
Avg P/E ratio x16.338.2 42.6%  
P/CF ratio (eoy) x15.921.3 74.9%  
Price / Book Value ratio x3.74.0 92.7%  
Dividend payout %29.725.7 115.8%   
Avg Mkt Cap Rs m21,157493,632 4.3%   
No. of employees `0000.522.7 2.2%   
Total wages/salary Rs m40031,068 1.3%   
Avg. sales/employee Rs Th13,787.46,259.0 220.3%   
Avg. wages/employee Rs Th813.01,369.8 59.4%   
Avg. net profit/employee Rs Th2,643.3569.7 464.0%   
INCOME DATA
Net Sales Rs m6,783141,961 4.8%  
Other income Rs m3531,715 20.6%   
Total revenues Rs m7,136143,676 5.0%   
Gross profit Rs m1,61724,722 6.5%  
Depreciation Rs m2710,266 0.3%   
Interest Rs m6634 0.9%   
Profit before tax Rs m1,93815,537 12.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6322,965 21.3%   
Profit after tax Rs m1,30112,921 10.1%  
Gross profit margin %23.817.4 136.9%  
Effective tax rate %32.619.1 171.0%   
Net profit margin %19.29.1 210.6%  
BALANCE SHEET DATA
Current assets Rs m6,98496,837 7.2%   
Current liabilities Rs m2,05684,199 2.4%   
Net working cap to sales %72.68.9 816.0%  
Current ratio x3.41.2 295.4%  
Inventory Days Days9973 135.3%  
Debtors Days Days2498 24.5%  
Net fixed assets Rs m244102,552 0.2%   
Share capital Rs m227829 27.4%   
"Free" reserves Rs m5,441121,792 4.5%   
Net worth Rs m5,668122,621 4.6%   
Long term debt Rs m255,449 0.5%   
Total assets Rs m7,901218,165 3.6%  
Interest coverage x353.325.5 1,385.3%   
Debt to equity ratio x00 9.9%  
Sales to assets ratio x0.90.7 131.9%   
Return on assets %16.56.2 266.0%  
Return on equity %22.910.5 217.7%  
Return on capital %34.012.9 263.9%  
Exports to sales %0.254.6 0.4%   
Imports to sales %36.39.4 388.7%   
Exports (fob) Rs m1577,520 0.0%   
Imports (cif) Rs m2,46513,274 18.6%   
Fx inflow Rs m1581,670 0.0%   
Fx outflow Rs m2,67726,355 10.2%   
Net fx Rs m-2,66255,315 -4.8%   
CASH FLOW
From Operations Rs m92321,444 4.3%  
From Investments Rs m317-18,404 -1.7%  
From Financial Activity Rs m-481-3,692 13.0%  
Net Cashflow Rs m759-1,144 -66.4%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 5.4 209.3%  
FIIs % 7.2 35.3 20.4%  
ADR/GDR % 0.0 18.5 -  
Free float % 30.4 15.3 198.7%  
Shareholders   21,978 75,885 29.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   J.B.CHEMICALS  SUVEN LIFE  IPCA LABS  CADILA HEALTHCARE  VENUS REMEDIES  

Compare WYETH LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - DR. REDDYS LAB COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS